Quan Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Samsara BioCapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+5 more
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalRA CapitalLAVOrbiMedVenrock
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
















